Now Reading
Psychedelic Science and Medicine News: May 8-14

Psychedelic Science and Medicine News: May 8-14

Psychedelic Science and Medicine Roundup May 8-14

With each passing week, we are seeing more and more advances in psychedelic research in the scientific and medical fields. As the body of work continues to grow, Truffle Report has compiled a roundup of major medical and scientific news from May 8 – 14 2021, making it easier for you to track these ongoing developments.

Chicago Startup Using Psychedelics to Treat Brain Injuries Goes Public in Canada
May 10, 2021 – Wesana, a startup led by former Chicago Blackhawk Daniel Carcillo using psychedelics to help people recover from brain injuries, is now a public company. The firm began trading on the Canadian Securities Exchange under the symbol “WESA.” The public listing is the result of a successful reverse takeover agreement with Canada-based Debut Diamonds Inc., which was first announced in February.

The First Phase 3 Success for Psychedelics Will Pave the Way for an Industry
May 11, 2021 Nature Medicine published the results of a study detailing a potential new treatment for PTSD using MDMA and psychotherapy. MDMA-assisted therapy was found to be very effective at reducing PTSD symptoms and improving daily functionality in the 42 treated participants, when compared with the 37 participants who received psychotherapy and a placebo drug. As the first Phase 3 trial of a psychedelic drug, the study is generating excitement among therapists and investors. 

Silo Wellness Partners with Kaivalya Kollectiv to Include 5-MeO-DMT in Psychedelic Portfolio Offering
May 12, 2021 – Silo Wellness Inc. announced it will expand its portfolio to also include 5-MeO-DMT through a partnership with Kaivalya Kollectiv, an Los Angeles-based wellness company that conducts psychedelic-integrated spiritual coaching as well as facilitated retreats in Mexico, Jamaica and Costa Rica. Through the partnership, Silo Wellness will operate two 5-MeO-DMT retreats in Jamaica, where it already conducts psilocybin-assisted retreats as well as mushroom and truffle cultivation workshops. 

Wake Network Receives Approval for Phase 2b Psilocybin Microdosing Trial
May 12, 2021 – Wake Network Inc. announced that it has received conditional ethics board approval from the Ministry of Health and Wellness in Jamaica to conduct a Phase 2b psilocybin microdosing clinical trial together with the University of the West Indies. The receipt of this ethics board approval marks the completion of the final step towards receiving conditional approval to begin the study.

ATMA Journey Centers Announces Two New Section 56 Exemptions Granted by Health Canada, Responding to Increasing Demand for Psychedelic Medicine
May 12, 2021 – ATMA Journey Centers Inc. announced that it has received notice of approval from Health Canada for two Alberta-based patients who had applied for a Section 56 Exemption to undergo legal psychedelic-assisted therapy.

See Also
CJ Spottswood

Silo Wellness Debuts New Psychedelic Retreats In Jamaica
May 12, 2021 – Silo Wellness is hosting a new series of “transformation vacations” in Jamaica. Taking place at an exclusive villa in Montego Bay, the retreats range from four to six days and are tailored to specific audiences including women, couples, and the LGBTQIA+ community.

Psychedelics Move to The Forefront of Innovative Research as the FDA Approves Large-Scale Testing
May 13, 2021 – Psychedelics are frequently being used in clinical settings on small numbers of patients, but are moving quickly toward larger-scale medical approval. The FDA recently approved large-scale human trials to determine whether MDMA and other psychedelics warrant approval for treatment. The result is a budding industry of psychedelic research and innovation that is quickly moving these alternative treatments to the forefront of the medical community’s attention.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Builds Alliances Ahead of Psychedelic Drug Trial for Eating Disorders
May 13, 2021 – Tryp Therapeutics is preparing for an upcoming Phase 2a clinical trial exploring treatment for eating disorders by forming partnerships with experienced healthcare professionals. The company’s recent announcement that it will collaborate with psychedelic therapy educational platform Fluence in a master service agreement to provide design and training for the psychotherapeutic portion of the upcoming trials follows Tryp’s agreement with the University of Florida to conduct the clinical trial.

View Comments (0)

Leave a Reply

Your email address will not be published.

Scroll To Top